Xeljanz
New ICER report reveals most cost-effective rheumatoid arthritis therapies
November 27, 2019Research and Development, Sales and Marketing AbbVie, Eli Lilly, Humira, Olumiant, Pfizer, Rinvoq, Xeljanz, pharma
The Institute for Clinical and Economic Review (ICER) has unveiled a new report comparing the clinical efficacy and cost-effectiveness of …
Top Ten most popular articles on Pharmafile.com this week
February 22, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Cancer, China, MedImmune, Xeljanz, asthma, diabetes, keytruda, osteoarthritis, pharma, rare disease
Happy Friday! With the weekend within reach, check out our run-down of the top ten most popular articles on Pharmafile.com …
Pfizer overhauls Xeljanz study over concerns of increased risk of pulmonary embolism and death
February 21, 2019Research and Development Pfizer, Xeljanz, pharma, rheumatoid arthritis
Pfizer is set to overhaul the dosing groups in its ongoing study of Xeljanz (tofacitinib) after an evaluation from a …
Pfizer notches two EU approvals, including Herceptin biosimilar
August 1, 2018Research and Development, Sales and Marketing Cancer, EMA, EU, Genetech, Herceptin, Pfizer, Trazimera, Xeljanz, biosimilar, breast cancer, pharma
Pfizer is patting itself on the back after securing two new approvals in Europe within 24 hours: Xeljanz (tofacitinib citrate) …
Pfizer’s Xeljanz scores EU approval for active psoriatic arthritis
June 29, 2018Medical Communications, Sales and Marketing EU, Europe, Pfizer, Xeljanz, pharma, psoriatic arthritis
Pfizer has announced that the European Commission (EC) has approved Xeljanz in combination with methotrexate (MTX) for the treatment of …
Pfizer’s Xeljanz becomes first JAK inhibitor approved in US for active ulcerative colitis
May 31, 2018Sales and Marketing FDA, Pfizer, US, Xeljanz, pharma, ulcerative colitis
Pfizer has revealed that its Janus kinase (JAK) inhibitor Xeljanz (tofacitinib) has received FDA approval for the treatment of adult …
FDA approves Pfizer’s Xeljanz for psoriatic arthritis
December 18, 2017Sales and Marketing FDA, Pfizer, Xeljanz, pharma, psoriatic arthritis
Pfizer has revealed that the FDA has passed marketing approval for Xeljanz (tofacitinib) for the treatment of active psoriatic arthritis …
Pfizer launches legal action to block Xeljanz copies in India
September 9, 2016Medical Communications, Sales and Marketing Pfizer, Sun Pharma, Xeljanz, Zydus Cadila, rheumatoid arthritis
Pfizer has pre-emptively sued a number of India-based drug companies including Sun Pharma and Zydus Cadila to block any attempts …
Revenue rises at Pfizer as Ibrance and Xeljanz beat sales expectations
August 2, 2016Research and Development, Sales and Marketing 2016, Pfizer, Prevnar, Q2, Xeljanz, ibrance, results
Pfizer has published its Q2 results, which show revenues rising 11% with new drugs helping to drive the growth and …
Ulcerative colitis treatment Xeljanz records positive top-line results in Phase III trial
July 29, 2016Medical Communications, Research and Development Pfizer, Xeljanz, tofacitinib, ulcerative colitis
Pfizer has announced positive top-line results from oral clinical trials for tofacitinib in ulcerative colitis (Octave) sustain, the third Phase …
Pfizer’s tofacitinib shows promise for psoriatic arthritis treatment in Phase III trial
April 5, 2016Medical Communications, Research and Development, Sales and Marketing Allergan, Pfizer, Xeljanz, merger, phase III, psoriatic arthritis, tofacitinib
Pfizer has announced positive top-line results from their latest Phase III study investigating Xeljanz (tofacitinib citrate). The OPAL Broaden trial …
EMA to review Pfizer’s Xeljanz for patients with rheumatoid arthritis
March 24, 2016Research and Development, Sales and Marketing EMA, Pfizer, Xeljanz, approval, authorisation, marketing, review, rheumatoid arthritis
Pfizer (NYSE: PFE) has announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorisation Application (MAA) …
Pfizer posts fourth-quarter revenue decline
January 28, 2015Sales and Marketing Eliquis, Lipitor, Lyrica (pregablin), Pfizer, Read, Xeljanz, apixaban, financials, pneumococcal vaccine Prevnar, q4, tofacitinib citrate
Pfizer posted a 3% decline in revenue in the last quarter of 2014, the company’s latest financial results show. The …
Pfizer’s Xeljanz rejected in Europe
April 28, 2013Sales and Marketing CHMP, Humira, Pfizer, RA, Xeljanz, rheumatoid arthritis
Pfizer has suffered a major setback with the rejection of its new arthritis drug in Europe.The EMA’s medicines committee the …
Latest content
Five Facts about cardiovascular disease
